Exploring the Anti-ageing Effects of Metformin in COPD
Status:
NOT_YET_RECRUITING
Trial end date:
2029-09-01
Target enrollment:
Participant gender:
Summary
Prospective, multicentre, double-blind, placebo-controlled, randomised, prospective clinical trial comparing the effect of metformin 850 mg twice daily with placebo in COPD patients with evidence of emphysema (by CT scan or reduced DLCO) who are known to have a rapid decrease in FEV1.
Main objective:
To compare the change in FEV1 at 3 years follow-up in patients receiving metformin versus placebo.
Participants will take metformin (850mg) or placebo twice daily for 3 years.
Phase:
PHASE3
Details
Lead Sponsor:
Fundacin Instituto de Investigacin Sanitaria de Navarra